Updated:
Kriya Therapeutics
Kriya Therapeutics is based in Palo Alto and was founded in 2019; the profile covers headquarters, registration, AUM band and key contacts for...
Overview
Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.
General information
Year founded
2019
Location
Region
North America
Country
United States
City
Palo Alto
Corporate office
Palo Alto, CA, United States
Principals
Shankar Ramaswamy
Co-Founder, Chairman and Chief Executive Officer
Roger Jeffs
Co-Founder and Vice Chairman
Fraser Wright
Scientific Co-Founder and Chief Gene Therapy Officer
Sachiyo Minegishi
Chief Financial Officer
Greg Di Russo
Chief Medical Officer
Britt Petty
Chief Manufacturing Officer
Michele Stone
Chief Scientific Officer
Brian Furmanski
Chief Development Officer
Mark Chen
Chief Operating Officer
Katherine Eade
Chief Legal Officer
C.R. Sincock, II
Founding Investor and Board Observer
Sector focus
Frequently asked questions
Who runs investment decisions at Kriya Therapeutics?
Kriya is a biopharmaceutical company, not an investment firm. The CEO, Shankar Ramaswamy, leads overall strategy. The company is backed by institutional investors including Patient Square Capital and Premji Invest, whose board representatives participate in governance.
How does Kriya source its therapeutic programs?
Kriya targets diseases with validated biological pathways and high unmet medical need, focusing on ophthalmology, metabolic, and neurologic conditions. Its scientific co-founder Fraser Wright and chief scientific officer Michele Stone lead target selection. The company's advisors include leading gene therapy researchers from Stanford and UMass Medical School.
Does Kriya manufacture its own gene therapies?
Yes. Kriya has an in-house manufacturing capability led by Chief Manufacturing Officer Britt Petty, who previously oversaw gene therapy manufacturing at AveXis and Biogen. This vertical integration is a deliberate structural choice, distinguishing Kriya from many gene therapy companies that outsource manufacturing.
What investment stages does Kriya typically target?
Kriya does not make investments; it raises venture capital and private equity for its own pipeline. The company has raised over $900 million since 2019 across seed, multiple follow-on rounds, and later-stage financing.
What is Kriya's known posture on partnerships and licensing?
Kriya has not publicly disclosed specific licensing deals. The company's website references a board member with experience forming strategic ventures, and its legal team includes IP expertise. The company's strategy emphasizes internal discovery and manufacturing rather than external licensing.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: